TICKERNERD
Menu
NSRXNSRXHealthcare · Drug Manufacturers - General

NSRX Stock Forecast: Nasus Pharma Ltd. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$3.19
+5.28% on the day

The 2 Wall Street analysts covering Nasus Pharma Ltd. hold a median 12-month price target of $19 — +495.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$35.5M
Ticker Nerd rank
4 / 100
Median analyst target
$19
Analysts covering
2
Total return, dividends reinvested
1W
+3.2%
1M
−8.9%
YTD
−65.1%
From high
−65.1%
From low
+58.7%
$2.01
$9.15
Range since 13 Aug 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

NSRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nasus Pharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
4 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
86
Revisions
60
Issuance
9
Growth
8
Accruals
8
Value
4
Quality
1
Volatility
0
Momentum
0

Size (86): Smaller than most of the companies we track.

Momentum (0): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own Nasus Pharma Ltd. — and when they’d sell — is the membership.

Wall Street

NSRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NSRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 13 Aug 2025Adjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26NSRXHigh $22Median $19Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $18Median $19High $22

The green dot is the last close — the median target sits +495.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Mar 2026CitizensMaintainsMarket Outperform—
18 Dec 2025CitizensInitiatesMarket Outperform—
29 Sept 2025Laidlaw & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

NSRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Nasus Pharma Ltd. (NSRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.2×

Cheaper than 89% of US stocks

Price / sales
—
Price / book
9.9×

Cheaper than 10% of US stocks

EV / EBITDA
−7.9×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−211.6%

Higher than 6% of US stocks

Return on assets
−107.1%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NSRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
NSRXNasus Pharma Ltd.$35.5M
4
MIRAMIRA Pharmaceuticals, Inc.$33.2M
17
SCLXScilex Holding Co.$56.6M
19
CCELCryo-Cell International, Inc.*$27.6M
72
HBIOHarvard Bioscience, Inc.*$27.3M
98
KYNBKyntra Bio, Inc.*$27.2M
67
BEATHeartBeam, Inc.*$26.8M
37

* Nearest Healthcare names by size — few drug manufacturers - general companies of this scale trade in the US universe.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NSRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest NSRX news & analysis

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth

GlobeNewsWire · 28 July 2026positive

Nasus Pharma announced the appointment of Brendan P. O'Grady as its new Chief Executive Officer, effective July 27, 2026, succeeding Dan Teleman. O'Grady is tasked with leading the Company's next growth phase, including commercializing NS002 and advancing its intranasal technology platform.

Why it matters — A leadership change at the CEO level signals a strategic shift for Nasus Pharma as it aims to commercialize its lead candidate NS002 and build value around its Nasax® platform, which could affect the company's direction and milestones for investors.

FAQ

Frequently asked questions about NSRX stock

What is the NSRX stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Nasus Pharma Ltd. have a median 12-month price target of $19, with estimates ranging from $18 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NSRX stock a buy right now?

Of the 2 analysts covering Nasus Pharma Ltd., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nasus Pharma Ltd. 4 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NSRX?

As at 1 Aug 2026, Nasus Pharma Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).

Will NSRX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +495.6% from the last close, and Ticker Nerd's factor model ranks Nasus Pharma Ltd. 4 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NSRX stock forecast for 2030?

No analyst covering Nasus Pharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NSRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $22 over the next 12 months.

What does Nasus Pharma Ltd. do?

Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company dedicated to the development of innovative powder-based intranasal therapies.

What is the latest news on NSRX?

The most recent item we track (GlobeNewsWire, 28 July 2026): "Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth". Nasus Pharma announced the appointment of Brendan P. O'Grady as its new Chief Executive Officer, effective July 27, 2026, succeeding Dan Teleman. O'Grady is tasked with leading the Company's next growth phase, including commercializing NS002 and advancing its intranasal technology platform.

Company

About Nasus Pharma Ltd.

Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company dedicated to the development of innovative powder-based intranasal therapies. The company’s primary focus is addressing acute medical conditions and urgent public health needs, utilizing proprietary microsphere technology to enable rapid, non-invasive drug delivery. Its product portfolio targets critical emergency situations, such as opioid overdose and anaphylactic shock, where immediate intervention is vital. Intranasal administration provides rapid absorption, ease of use, and does not require injection, making treatments more accessible to patients, caregivers, and first responders. Nasus Pharma’s technology has demonstrated significantly enhanced absorption rates compared to traditional solution-based drugs, supporting its relevance in life-threatening scenarios. Headquartered in Israel, the company’s work is particularly significant for advancing care standards in emergency medicine and holds potential for broader applications in the healthcare sector by improving the speed and effectiveness of drug delivery in acute settings.

CEO Mr. Dan Teleman MBA M.Sc. · 7 employees · Israel · https://www.nasuspharma.com